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Inherited metabolic storage cardiomyopathies, often clinically misdiagnosed, comprise a 
small, but important, fraction of patients genotyped with clinical suspicion of hypertrophic 
cardiomyopathy (HCM, ≤1%). Overall, glycogen metabolism disorders affect energy 
homeostasis primarily in skeletal muscle, heart, liver, and, less frequently, the central nervous 
system. These rare diseases are quite variable regarding age of onset, symptoms, morbidity and 
mortality. Typical pathologic vacuoles containing glycogen or intermediary metabolites altering 
cardiac structure and function are usually described in Pompe’s, Danon’s and Fabry’s diseases as 
well as in patients with mutations in PRKAG2, the regulatory γ subunit of AMP-activated protein 
kinase. In affected patients, these multisystem disorders may cause left ventricular hypertrophy 
that could accompany neuromuscular deficits, liver and/or kidney dysfunction and abnormalities 
of the peripheral central nervous system (1, 2). 
Lafora disease (LD) is a rare neurodegenerative disease (<5/1,000,000) mainly present in 
Mediterranean countries and consanguineous regions, although its exact prevalence is unknown. 
It manifests during adolescence with neurological symptoms that eventually lead patients to a 
vegetative state and premature death. There is no treatment available, apart from antiepileptic 
drugs and palliative support. LD is caused by mutations in laforin (EPM2A) or malin (EPM2B), 
which are key regulators of glycogen metabolism. LD patients show abnormal glycogen deposits 
called Lafora bodies, in brain, skeletal muscle, skin, liver and also in the heart. The accumulation 
of Lafora bodies as a result of laforin or malin deficiency has recently led some authors to 
consider Lafora disease as a new member of the family of glycogen storage diseases (3). 
Although rhythm disturbances and heart failure have been reported in some Lafora disease 
patients (4), the consequences of laforin or malin loss for cardiac function over time have not 
been explored. 
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To address this question, we blindly assessed cardiac function and remodeling in two 
previously described mouse models of LD, lacking either laforin (Epm2a-/-) or malin (Epm2b-/-), 
which show evident neurological abnormalities beginning at 8-10 months of age (5). 
Experiments were conducted in accordance with the guidelines of the Institutional Animal 
Welfare Committee. Echocardiography analysis, performed in two separate groups of mice at 8-
10 months of age and at 14-16 months of age under light anesthesia, revealed that laforin and 
malin knockout mice develop cardiac hypertrophy and marked systolic dysfunction by 14-16 
months of age, showed by an increased end-diastolic left ventricle walls thickness and 
normalized cardiac mass, and a decreased left ventricle ejection fraction (Table 1). Histological 
assessment showed abundant glycogen aggregates inside the cardiomyocytes, including typical 
Lafora bodies, and increased cardiomyocytes area in both LD mouse lines. In addition, LD mice 
showed increased normalized cardiac weight (heart weight to tibial length ratio) and BNP 
expression, confirming the presence of cardiac hypertrophy and dysfunction (Table 1).  
These pathological features resemble the inherited metabolic cardiomyopathies of human 
multisystem glycogen-storage disorders caused by mutations in genes regulating glycogen 
metabolism. Overall, our results strongly suggest that cardiac studies should be systematically 
performed in patients with LD, that laforin and malin deficiency should be considered part of the 
genetic spectrum of metabolic HCM, and that HCM patients with an unknown underlying 
genetic cause might benefit from genetic screening of laforin and malin genes, especially if 
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Table 1. Cardiac parameters in wild type mice compared to laforin and malin knockout 
mice. 
        
 8-10 months of age  14-16 months of age 
 WT Epm2a-/- Epm2b-/-  WT Epm2a-/- Epm2b-/- 
LAX two-dimensional echocardiography data 










































N 5 6 6  11 12 12 
Gravimetric and histological analysis 
HW/TLenth (mg/mm) 







BNP expression (fold 
induction) 
 













PAS positive     - +++ +++ 
N     7 8 8 
        
LVVold, end-diastolic left ventricle volume; LVVols, end-systolic left ventricle volume;  LVEF, 
left ventricle ejection fraction; HW, heart weight; TL, tibial length; PAS, Periodic Acid-Schiff 
staining in heart sections; N, number of mice. Data are presented as mean±SD.  *P<0.05, 
**P<0.01, ***P<0.001 Epm2a-/- vs WT and Epm2b-/- vs WT; #P<0.05, ##P<0.01, ###P<0.001 
Epm2a-/- and Epm2b-/- 8-10m vs Epm2a-/-and Epm2b-/- 14-16m, respectively, using a two-way 
ANOVA test with Bonferroni correction, or a Student t test for HW/TL, cardiomyocytes area and 
BNP expression.  
